Rationale and uses of a public HIV drug-resistance database.

TitleRationale and uses of a public HIV drug-resistance database.
Publication TypeJournal Article
Year of Publication2006
AuthorsShafer RW
JournalJ Infect Dis
Volume194 Suppl 1
PaginationS51-8
Date Published2006 Sep 15
ISSN0022-1899
KeywordsAnti-HIV Agents, Clinical Trials as Topic, Databases, Factual, Drug Resistance, Viral, HIV Infections, HIV Protease, HIV Reverse Transcriptase, HIV-1, Humans
Abstract

Knowledge regarding the drug resistance of human immunodeficiency virus (HIV) is critical for surveillance of drug resistance, development of antiretroviral drugs, and management of infections with drug-resistant viruses. Such knowledge is derived from studies that correlate genetic variation in the targets of therapy with the antiretroviral treatments received by persons from whom the variant was obtained (genotype-treatment), with drug-susceptibility data on genetic variants (genotype-phenotype), and with virological and clinical response to a new treatment regimen (genotype-outcome). An HIV drug-resistance database is required to represent, store, and analyze the diverse forms of data underlying our knowledge of drug resistance and to make these data available to the broad community of researchers studying drug resistance in HIV and clinicians using HIV drug-resistance tests. Such genotype-treatment, genotype-phenotype, and genotype-outcome correlations are contained in the Stanford HIV RT and Protease Sequence Database and have specific usefulness.

DOI10.1086/505356
Alternate JournalJ. Infect. Dis.
PubMed ID16921473
PubMed Central IDPMC2614864
Grant ListR01 AI068581 / AI / NIAID NIH HHS / United States
R01 AI068581-03 / AI / NIAID NIH HHS / United States